Metamizol Stada (Metamizole Sodium Monohydrate)

Metamizole sodium works by inhibiting cyclooxygenase enzymes, which reduces the production of prostaglandins. Lower prostaglandin levels decrease peripheral pain signaling and reset the hypothalamic temperature set‑point, providing both analgesic and antipyretic effects.

The specific dose of Metamizol Stada is determined by the prescribing clinician based on the patient’s condition, age, weight, and response to therapy. Healthcare professionals follow national guidelines and adjust the regimen as needed.

Safety data for metamizole sodium during pregnancy and lactation are limited. Because potential risks cannot be ruled out, it is generally advised to avoid use in pregnant or breastfeeding women unless the benefits clearly outweigh the risks and no safer alternative is available.

To request Metamizol Stada, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metamizole belongs to the pyrazolone class, offering analgesic and antipyretic effects similar to NSAIDs but with a distinct safety profile. Unlike opioids, it does not cause respiratory depression, yet it carries a rare risk of agranulocytosis, which is less common with many traditional NSAIDs.

Metamizol Stada should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, excessive heat and direct sunlight to maintain its stability and potency throughout its shelf life.

Metamizol Stada is administered orally. The tablet (or other oral form) should be swallowed whole with water and taken according to the prescriber’s instructions, typically with or without food as directed.

The most serious adverse events associated with metamizole sodium include agranulocytosis, a potentially life‑threatening drop in white blood cells, and severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome. Immediate medical attention is required if signs of infection, rash, or breathing difficulty develop.

Metamizol Stada should be avoided in individuals with known hypersensitivity to metamizole or other pyrazolones, patients with a history of agranulocytosis or severe blood dyscrasias, and those with uncontrolled hypotension. Caution is also advised for patients with significant liver or kidney impairment.